Marcela V. Maus, M.d.,ph.d.

This early-phase trial tests a new treatment called CC-97540, which uses a patient's own immune cells engineered to target and destroy harmful B cells. It is for 12 adults with severe ANCA-associated vasculitis that has not responded to standard therapies. The main goals are to c…

This early-stage trial tests a new treatment called CARv3-TEAM-E T cells for people with glioblastoma, a serious brain cancer that has come back. The therapy uses the patient's own immune cells, modified in a lab to better attack the cancer, and is given directly into the brain f…

This study tests whether the drug emapalumab can prevent severe cytokine release syndrome (CRS), a common and serious side effect of CAR-T cell therapy, in adults with certain types of non-Hodgkin lymphoma that have come back or not responded to treatment. About 28 participants w…

This early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins, CD79b and CD19, on lymphoma cells. It is for people with non-Hodgkin lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to chec…

This early-phase study tests a new treatment called TriPRIL CAR T cells for people with multiple myeloma that has returned or not responded to standard therapies. About 18 adults will receive the therapy along with two chemotherapy drugs to prepare the body. The main goal is to c…

This study follows 45 adults who previously received CAR T cell therapy in earlier trials. Researchers will track their health for years using scans, blood tests, and physical exams to see how long the treatment's effects last and whether any late side effects appear. The goal is…